Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic DataChristoph P. Hornik, Daniel González, Huali Wu et al.|Clinical Pharmacokinetics|2017Cited by 45
Characterizing Pharmacokinetics in Children With Obesity—Physiological, Drug, Patient, and Methodological ConsiderationsJacqueline G. Gerhart, Daniel González, Stephen J. Balevic et al.|Frontiers in Pharmacology|2022Cited by 40
Physiologically‐Based Pharmacokinetic Modeling Characterizes the CYP3A‐Mediated Drug‐Drug Interaction Between Fluconazole and Sildenafil in InfantsSara Salerno, Daniel González, Andrea N. Edginton et al.|Clinical Pharmacology & Therapeutics|2020Cited by 40
Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic ModelingJacqueline G. Gerhart, Robert H. Lurie, Gregory L. Kearns et al.|Clinical Pharmacokinetics|2021Cited by 39
Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected SubjectsAnil R. Maharaj, Andrea N. Edginton, Daniel González et al.|Clinical Pharmacokinetics|2017Cited by 34